Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0639
Source ID: NCT00453973
Associated Drug: Peginesatide
Title: Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU)
Acronym:
Status: TERMINATED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT00453973/results
Conditions: Chronic Renal Failure|Chronic Kidney Disease|Anemia
Interventions: DRUG: peginesatide|DRUG: peginesatide
Outcome Measures: Primary: Proportion of Participants With Mean Hemoglobin in the Target Range of 10.0-12.0 Grams Per Deciliter (g/dL) After Final Dosing Guideline Change, Up to 54 months |
Sponsor/Collaborators: Sponsor: Affymax
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 114
Study Type: INTERVENTIONAL
Study Designs: Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2006-11
Completion Date: 2009-09
Results First Posted: 2012-05-28
Last Update Posted: 2012-06-29
Locations: Research Facility, Burgas, 8000, Bulgaria|Research Facility, Pleven, 5800, Bulgaria|Research Facility, Plovdiv, 4003, Bulgaria|Research Facility, Rousse, 7002, Bulgaria|Research Facility, Varna, 9010, Bulgaria|Research Facility, Veliko Tarnovo, 5000, Bulgaria|Research Facility, Białystok, 15-540, Poland|Research Facility, Katowice, 40-027, Poland|Research Facility, Łódź, 90-153, Poland|Research Facility, Arad, 310017, Romania|Research Facility, Bacau, 600114, Romania|Research Facility, Bucuresti, 014461, Romania|Research Facility, Iasi, 700506, Romania|Research Facility, Timisoara, 300736, Romania|Research Facility, Croydon, CR7 7YE, United Kingdom|Research Facility, Derby, DE22 3NE, United Kingdom|Research Facility, London, E1 1BB, United Kingdom|Research Facility, London, SES 9RS, United Kingdom|Research Facility, London, SW17 0QT, United Kingdom|Research Facility, Swansea, SA6 6NL, United Kingdom
URL: https://clinicaltrials.gov/show/NCT00453973